ASLAN Pharmaceuticals Statistics Share Statistics ASLAN Pharmaceuticals has 2.83M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 2.83M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 0% Shares Floating 16.41M Failed to Deliver (FTD) Shares 995 FTD / Avg. Volume 0.97%
Short Selling Information The latest short interest is 55.57K, so 1.96% of the outstanding
shares have been sold short.
Short Interest 55.57K Short % of Shares Out 1.96% Short % of Float 2.11% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.06 and the forward
PE ratio is -0.06.
ASLAN Pharmaceuticals's PEG ratio is
0.
PE Ratio -0.06 Forward PE -0.06 PS Ratio 0.23 Forward PS 0.3 PB Ratio -0.21 P/FCF Ratio -0.06 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ASLAN Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.84,
with a Debt / Equity ratio of -2.02.
Current Ratio 1.84 Quick Ratio 1.84 Debt / Equity -2.02 Debt / EBITDA -0.62 Debt / FCF -0.58 Interest Coverage -10.11
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $342.86K Profits Per Employee $-1.26M Employee Count 35 Asset Turnover 0.49 Inventory Turnover n/a
Taxes Income Tax 132.67K Effective Tax Rate -0.3%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.4, so ASLAN Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.4 52-Week Price Change n/a 50-Day Moving Average 1.78 200-Day Moving Average 4.17 Relative Strength Index (RSI) 21.61 Average Volume (20 Days) 102,493
Income Statement In the last 12 months, ASLAN Pharmaceuticals had revenue of 12M
and earned -44.22M
in profits. Earnings per share was -67.25.
Revenue 12M Gross Profit 11.65M Operating Income -43.74M Net Income -44.22M EBITDA -43.39M EBIT -39.75M Earnings Per Share (EPS) -67.25
Full Income Statement Balance Sheet The company has 21.25M in cash and 26.83M in
debt, giving a net cash position of -5.57M.
Cash & Cash Equivalents 21.25M Total Debt 26.83M Net Cash -5.57M Retained Earnings -321.07M Total Assets 20.99M Working Capital 972.05K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -46.36M
and capital expenditures -10.78K, giving a free cash flow of -46.37M.
Operating Cash Flow -46.36M Capital Expenditures -10.78K Free Cash Flow -46.37M FCF Per Share -70.47
Full Cash Flow Statement Margins Gross margin is 97.1%, with operating and profit margins of -364.46% and -368.5%.
Gross Margin 97.1% Operating Margin -364.46% Pretax Margin -367.32% Profit Margin -368.5% EBITDA Margin -361.56% EBIT Margin -364.46% FCF Margin -386.42%
Dividends & Yields ASLN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ASLN is $72,
which is 11900% higher than the current price. The consensus rating is "Buy".
Price Target $72 Price Target Difference 11900% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 3, 2024. It was a
backward
split with a ratio of 1:8.
Last Split Date Jul 3, 2024 Split Type backward Split Ratio 1:8
Scores Altman Z-Score -26.87 Piotroski F-Score 3
